References
- 1Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res. 2009; 2(1): 4. DOI: 10.1186/1756-6614-2-4
- 2Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001; 344(7): 501–9. DOI: 10.1056/NEJM200102153440707
- 3Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: A correctable cause of “idiopathic” atrial fibrillation. Am J Cardiol. 1979; 44(1): 9–12. DOI: 10.1016/0002-9149(79)90243-1
- 4Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994; 331(19): 1249–52. DOI: 10.1056/NEJM199411103311901
- 5Chen Q, Yan Y, Zhang L, Cheng K, Liu Y, Zhu W. Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation. Cardiology. 2014; 127(3): 176–82. DOI: 10.1159/000356954
- 6Burggraaf J, Lalezari S, Emeis JJ, et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid. 2001; 11(2): 153–60. DOI: 10.1089/105072501300042820
- 7Sato Y, Sato Y, Kakisako S, Honda Y, Kaji M. Cerebral embolism and hyperthyroidism. The Kurume Med J. 1989; 36(1): 23–7. DOI: 10.2739/kurumemedj.36.23
- 8Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016; 37(38): 2893–2962. DOI: 10.1093/eurheartj/ehw210
- 9Poulin MF, Doukky R. Hyperthyroid atrial fibrillation: Does it matter for stroke risk? Cardiology. 2014; 128(1): 51–3. DOI: 10.1159/000357613
- 10Siu CW, Pong V, Zhang X, et al. Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. Heart Rhythm. 2009; 6(2): 169–73. DOI: 10.1016/j.hrthm.2008.10.023
- 11Nakazawa HK, Handa S, Nakamura Y, et al. High maintenance rate of sinus rhythm after cardioversion in post-thyrotoxic chronic atrial fibrillation. Int J Cardiol. 1987; 16(1): 47–55. DOI: 10.1016/0167-5273(87)90269-5
- 12Tsai MS, Chuang PY, Huang CH, et al. Better adherence to antithyroid drug is associated with decreased risk of stroke in hyperthyroidism patients. Int J Clin Pract. 2015; 69(12): 1473–85. DOI: 10.1111/ijcp.12724
- 13Lin LY, Warren-Gash C, Smeeth L, Chen PC. Data resource profile: The National Health Insurance Research Database (NHIRD). Epidemiol Health. 2018; 40:
e2018062 . DOI: 10.4178/epih.e2018062 - 14Chang CH, Lee YC, Tsai CT, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis. 2014; 232(1): 224–30. DOI: 10.1016/j.atherosclerosis.2013.11.036
- 15Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Me Assoc. 2015; 114(3): 254–9. DOI: 10.1016/j.jfma.2013.09.009
- 16Siu CW, Jim MH, Zhang X, et al. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation. Am J Cardiol. 2009; 103(4): 540–3. DOI: 10.1016/j.amjcard.2008.10.019
- 17Nakazawa H, Lythall DA, Noh J, et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J. 2000; 21(4): 327–33. DOI: 10.1053/euhj.1999.1956
- 18Chen YC, Chen SA, Chen YJ, Chang MS, Chan P, Lin CI. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Col Cardiol. 2002; 39(2): 366–72. DOI: 10.1016/S0735-1097(01)01731-4
- 19Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: An analysis of > 10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 2014; 35(8): 508–16. DOI: 10.1093/eurheartj/eht491
- 20Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest. 2014; 146(5): 1187–95. DOI: 10.1378/chest.14-0003
- 21Bruere H, Fauchier L, Bernard Brunet A, et al. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. Am J Med. 2015; 128(1): 30–7. DOI: 10.1016/j.amjmed.2014.07.014
- 22Chan PH, Hai J, Yeung CY, et al. Benefit of anticoagulation therapy in hyperthyroidism-related atrial fibrillation. Clinical cardiology. 2015; 38(8): 476–82. DOI: 10.1002/clc.22427
- 23Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: A population-based cohort study. Br J Clin Pharmacol. 2014; 78(3): 619–29. DOI: 10.1111/bcp.12336
- 24Akmal A, Kung J. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. Expert Opin Drug Saf. 2014; 13(10): 1397–406. DOI: 10.1517/14740338.2014.953796
- 25Gamra H, Murin J, Chiang CE, et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey. Arch Cardiovasc Dises. 2014; 107(2): 77–87. DOI: 10.1016/j.acvd.2014.01.001
- 26Hsieh FI, Lien LM, Chen ST, et al. Get With the Guidelines-Stroke performance indicators: Surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation. 2010; 122(11): 1116–23. DOI: 10.1161/CIRCULATIONAHA.110.936526
- 27Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: The decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011; 4(1): 14–21. DOI: 10.1161/CIRCOUTCOMES.110.958108
- 28Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Col Cardiol. 2007; 50(21): 2156–61. DOI: 10.1016/j.jacc.2007.07.076
- 29Wong CL, Tam HV, Fok CV, Lam PE, Fung LM. Thyrotoxic atrial fibrillation: Factors associated with persistence and risk of ischemic stroke. J Thyroid Res. 2017; 2017:
4259183 . DOI: 10.1155/2017/4259183 - 30Baumgartner C, da Costa BR, Collet TH, et al. Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation. Circulation. 2017; 136(22): 2100–16. DOI: 10.1161/CIRCULATIONAHA.117.028753